AI Article Synopsis
- Phantom limb pain (PLP) affects up to 85% of amputees and is challenging to treat, with memantine showing potential benefits in some pain cases.
- A systematic review of studies from MEDLINE and Embase found eight relevant articles, with some evidence supporting memantine's effectiveness in treating acute PLP, but not chronic PLP lasting over a year.
- Memantine was well tolerated, suggesting it may be a viable treatment option for recent amputees or those struggling with other pain medications, though more research is needed to confirm its effectiveness and identify ideal patients.
Article Abstract
Phantom limb pain (PLP) occurs in up to 85% of patients who have undergone an amputation and remains difficult to treat. Memantine is a N-Methyl-d-aspartate receptor antagonist that has shown benefit in pain syndromes. The objective of this systematic review is to evaluate the evidence for the use of memantine in the treatment of acute and chronic PLP. MEDLINE (1956 to May 2016) and Embase (1957 to May 2016) were queried for articles that characterized the clinical outcomes of patient(s) treated with memantine for PLP. The initial search identified 185 studies and case reports. After screening, eight articles were included. One prospective study, a case report, and two case series demonstrated benefit with memantine in the treatment of acute PLP. However, in chronic PLP that persisted for over 1 year, four prospective studies failed to demonstrate significant analgesic effects with memantine. Memantine was well tolerated in all studies. Memantine appears to be a reasonable option to trial in a patient with a recent amputation or who has failed or cannot tolerate other analgesics. Additional research is needed to further determine the role of memantine in the treatment and prevention of PLP and to identify the population most likely to gain benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15360288.2016.1241334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing proteasome activity by NMDAR antagonists explains their therapeutic effect in neurodegenerative and mental diseases.
Sci Rep
January 2025
Department of Histology and Embryology, Ankara University School of Medicine, Ankara, Turkey.
NMDAR antagonists, such as memantine and ketamine, have shown efficacy in treating neurodegenerative diseases and major depression. The mechanism by which these drugs correct the aforementioned diseases is still unknown. Our study reveals that these antagonists significantly enhance 20S proteasome activity, crucial for degrading intrinsically disordered, oxidatively damaged, or misfolded proteins, factors pivotal in neurodegenerative diseases like Alzheimer's and Parkinson's.
View Article and Find Full Text PDFNegative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
CNS Drugs
January 2025
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
Article Synopsis
- The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
- This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
- Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients.
J Alzheimers Dis
January 2025
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden.
Background: Medications for comorbid conditions may affect cognition in Alzheimer's disease (AD).
Objective: To explore the association between common medications and cognition, measured with the Mini-Mental State Examination.
Methods: Cohort study including persons with AD from the Swedish Registry for Cognitive/Dementia Disorders (SveDem).
A Narrative Review on the Neuroprotective Potential of Brown Macroalgae in Alzheimer's Disease.
Nutrients
December 2024
Foodomics Lab, Institute of Food Science Research (CIAL, CSIC), 28049 Madrid, Spain.
Systematic Alzheimer's disease (AD) is a neurodegenerative disease increasingly prevalent in the aging population. AD is characterized by pathological features such as -amyloid (A) plaque accumulation, tau neurofibrillary tangles formation, oxidative stress, an impaired cholinergic system, and neuroinflammation. Many therapeutic drugs have been developed to slow the progression of AD by targeting these pathological mechanisms.
View Article and Find Full Text PDFDeep Brain Stimulation Combined with NMDA Antagonist Therapy in the Treatment of Alzheimer's Disease: In Silico Trials.
J Clin Med
December 2024
Division of Biostatistics and Neural Networks, Medical University of Gdansk, Debinki 1 St., 80-211 Gdansk, Poland.
: Deep brain stimulation (DBS) is employed to adjust the activity of impaired brain circuits. The variability in clinical trial outcomes for treating Alzheimer's disease with memantine is not yet fully understood. We conducted a randomized in silico study comparing virtual DBS therapies with treatment involving an NMDA antagonist combined with DBS in patients with Alzheimer's disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!